Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 2261       

   Table of Contents      
ORIGINAL ARTICLE
Year : 2011  |  Volume : 134  |  Issue : 4  |  Page : 452-457

Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes


1 Department of Haematology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Anatomy, All India Institute of Medical Sciences, New Delhi, India

Date of Submission22-Jan-2009
Date of Web Publication15-Nov-2011

Correspondence Address:
Renu Saxena
Department of Haematology, IRCH Building (1st Floor), All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 22089606

Rights and PermissionsRights and Permissions
   Abstract 

Background & objectives : Myelodysplastic syndrome (MDS) is a clonal haematopoietic stem cell disorder characterized by ineffective haematopoiesis and leukaemia progression. Cytogenetic analysis has proven to be a mandatory part of the diagnosis of MDS as well as a major indicator for predicting clinical course and outcome. Studies on cytogenetics of MDS are reported mostly from the West and only a few are available from Asian countries. We report herein cytogenetic studies on 40 Indian patients with primary MDS to find out the occurrence and type of chromosome abnormalities and recurring defects.
Methods: Cytogenetic analysis was done using GTG banding and karyotyped according to the International System for Human Cytogenetic Nomenclature (ISCN).
Results: Of the 40 patients, 19 patients (47.5%) showed clonal karyotypic abnormalities with distribution as follows: 3 of 15 (20%) of refractory anaemia (RA), 4 of 7 (57%) of refractory anaemia with excess blasts-1 (RAEB-1), 4 of 6 (67%) of refractory anaemia with excess blasts 2 (RAEB-2), 2 of 3 (67%) of refractory anaemia with ring sideroblasts (RARS), 2 of 4 (50%) of refractory cytopenia with multilineage dysplasia (RCMD), none (0%) RCMD-ringed sideroblasts (RCMD-RS) and 4 patients with 5q syndrome. The frequent abnormalities observed in our study were -7, 5q-and trisomy 8.
Interpretation & conclusions: Two rare chromosomal abnormalities (6q-, 3q-) were found with unknown prognostic significance. Hence, cytogenetic analysis may be incorporated in the routine diagnosis of MDS since there are racial differences in clinical pictures and the molecular events.

Keywords: AML - chromosomal abnormalities - cytogenetics - myelodysplastic syndromes


How to cite this article:
Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res 2011;134:452-7

How to cite this URL:
Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res [serial online] 2011 [cited 2020 Jul 2];134:452-7. Available from: http://www.ijmr.org.in/text.asp?2011/134/4/452/89865

The myelodysplastic syndromes (MDSs) are a heterogenous group of clonal haematopoietic stem cell disorders that cause one or more peripheral cytopenias due to ineffective haematopoiesis [1] . MDS are associated with a high risk of progression to acute leukaemia and with an overall short survival, death being generally due to the consequences of cytopenias or progression to acute leukaemia [2] . A succession of MDS classification systems have been developed to facilitate prediction of the risk of progression to acute myeloid leukaemia (AML) and overall survival. The first of these was the French-American-British (FAB) system based on cytomorphologic abnormalities and blast percentage [3] . Recently, the World Health Organization (WHO) classification [4] proposed the following groups: RA (refractory anaemia), RARS (refractory anaemia with ringed sideroblast), RCMD (refractory cytopenia with multilineage dysplasia), RAEB (refractory anaemia with excess blasts), MDS - U (MDS unclassifiable), and MDS associated with isolated del(5q) chromosome abnormality. Two categories are recognized within the RAEB group: RAEB-1 defined by 5-9 per cent blasts in the bone marrow and <5 per cent blasts in the blood, and RAEB-2, defined by 10-19 per cent blasts in the bone marrow. The WHO classification is more stringent than the FAB classification regarding the percentage of blasts [4] .

Chromosomal abnormalities are detected in approximately 50 per cent of patients with de novo MDS and up to 80 per cent in patients with MDS secondary to chemotherapy or other toxic agents [5] . The clonal chromosomal changes are of both numerical and structural types. The most frequently occurring single abnormalities include mainly -5/del (5q),-7/del (7q), del (11q), del (12p)/ (12q),-y and +8. It is observed that the MDS patients from India are younger than those reported from the West and have severe clinical presentation. The response to treatment in these is poorer than the western patients [2],[6] . In view of this, we did conventional cytogenetics in MDS patients attending a tertiary care hospital in New Delhi, India, to find out the occurrence and types of chromosome abnormalities as also recurring defects.


   Material & Methods Top


Patients: Cytogenetic analysis was performed on 70 randomly selected de novo MDS patients including both new and old cases, presenting to the OPD of Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, between January 2006 to December 2007. Of the 70 samples, 40 were successfully karyotyed. Follow up data were available for 11 patients. Samples from the old cases were taken when they visited the OPD for follow up. Patients with an ambiguous diagnosis of MDS, those who had previously received chemo/radiotherapy, and those with MDS secondary to a previous malignancy were excluded from the analysis. Patients were treated with lenalidomide or cyclosporine and supportive care. Informed consent was obtained from all patients for the collection of bone marrow (BM) and peripheral blood (PB) samples. The ethical committee of the institute approved the study protocol.

Methods: From each patient 0.2-0.5 ml bone marrow or 1 x 10 6 cells were taken in heparin and cultured in RPMI 1640 (Gibco, USA) supplemented with 20 per cent foetal calf serum (FCS), 2 mM L-glutamine, penicillin and streptomycin (100U/ml) for 72 and 24 h respectively. Colcimid (Gibco) was added two hours before harvesting at a final concentration of 0.1μg/ml. The cells were then treated with hypotonic KCl (Sigma, USA) (0.075 M) for 12-15 min and fixed with methanol/acetic acid (Merck) (3:1 v/v). Cell suspension was dropped on clean chilled slides and flame dried. Gimsa Trypsin Gimsa (GTG) banding was performed by prior trypsinization and subsequent staining with Gimsa and karyotyped according to the International System for Human Cytogenetic Nomenclature (ISCN) [7] . At least 20 metaphases were analyzed to demonstrate the clonal nature of the aberrations.


   Results Top


Patients characteristics: The median age of patients was 42 yr (range 14-75 yr M:F: 1:1.2). Twenty six patients (65%) were under 46 yr and five patients were below 20 yr. Using FAB criteria, 24 (60%) were classified as having refractory anaemia (RA). The other FAB subgroups were as follows: RA with ringed sideroblasts (RARS), 3 (7.5%); RA with excess blasts 11 (27.5%); RA with excess blasts in transformation 2 (5%); chronic myelomonocytic leukaemia 0 (0%). According to WHO criteria, 15 (37.5%) had RA, 3 (7.5%) had RARS, 4 (10%) had 5q- syndrome, and refractory cytopenia with multilineage dysplasia (RCMD), 1 (2.5%) had RCMD-RS, 7 (17.5%) had RAEB-1, and 6 (15%) had RAEB-II [Table 1].
Table 1: Baseline characteristics of patients with MDS

Click here to view


Cytogenetics: Of the 40 patients karyotyped, 21 (52.5%) had normal cytogenetics and 19 patients (47.5%) had chromosomal abnormalities. The distribution was as follows: 3 of 15 (20%) of RA, 4 of 7 (57%) of RAEB-1, 4 of 6 (67%) of RAEB-II, 2 of 3 (67%) of RARS, 2 of 4 (50%) of RCMD and 0 of 1 (0%) RCMD-RS [Table 2]. Detailed karyotypes are given in [Table 3].
Table 2: Cytogenetic profile of patients with MDS (n=40)

Click here to view
Table 3: WHO subtypes and karyotype of MDS patients (n=40)

Click here to view


Monosomy 7 was the most frequent cytogenetic abnormality detected in 6 of 19 (32%) patients, followed by deletion 5q -detected in four (21%) and trisomy 8 in three (16%) patients; deletion 3q and deletion 6q were observed in two (11%) of cases. Other abnormalities in each case included isochromosome 9q and complex karyotype.

Transformation to AML: Of the 40 patients studied, two (5%) progressed to AML. The first patient who had RAEB-I, was diagnosed as MDS with monosomy 7 in September 2006 and transformed to AML-M2 in March 2007. The other patient diagnosed as RAEB-II with trisomy 8 transformed to acute leukaemia within 10 months. Of the patients with normal karyotype, none transformed to acute leukaemia, but one patient initially diagnosed as RA with normal karyotype in May 2007 transformed to RCMD in December 2007. The cytogenetics of this patient was repeated, when it transformed but there was no change in it. One patient with RARS who also had normal karyotype died after seven months from the time of diagnosis.


   Discussion Top


Cytogenetic abnormalities are the major determinants in pathogenesis, diagnosis, and prognosis, thus, form the basis for the selection of drugs in individual patients with MDS [1] . MDS show a characteristic genetic profile with an overweighing of unbalanced abnormalities. The incidence of clonal defects ranges between 32-76 per cent [8],[9] .

In our study, the mean number of metaphases analysed was 20, which is consistent with the criteria for high-quality cytogenetics studies in MDS. By contrast, the frequencies of chromosomal abnormalities previously reported by others were often based on analyses with fewer (>10) metaphases thus, increasing the probability of missing an anomaly [9] .

Studies on MDS are mostly reported from Japan in a large number of patients [10],[11],[12],[13] , with the exception of a few studies from other countries [2],[6],[14],[15],[16],[17] . In Europe, MDS is a disease of the elderly and the median age of patients at the time of diagnosis varies between 65 and 74 yr [18] . In our study the median age of patients at diagnosis was 42 yr which is in concordance with reports from Southeast Asia, Turkey and Central Africa. It has been reported that MDS patients in these areas are generally younger than those from Western countries [10],[14],[15] , and the reason for this difference is not clear. However, it is speculated that the younger age of Asian patients may be due to differential action of various environmental factors, including an increase in exposure to aetiologically relevant risk factors such as organic solvents, pesticides, radiation and environmental pollution [6] .

The incidence of clonal abnormalities in MDS varies between 23-78 per cent. Cytogenetic abnormalities in MDS are associated with a strong prognostic value and in the pathogenesis of the disease [10] . The frequency of clonal cytogenetic abnormalities was 47.5 per cent among patients with primary MDS in our study which is in agreement with published literature [18],[19] . The frequency in the low risk group (RA, RARS and 5q syndrome) was 41 per cent and in high risk group (RAEB1, RAEB2 and RCMD) 55 per cent in concordance to that reported in the literature [8] . In the present study, the most common chromosomal abnormalities were of -7,del(5q),+8,del(6q) and del (3q) in the decreasing order of preponderance. It was similar to the most of the Western studies [4],[5],[9] except for the del (6q) and del (3q) which were not reported as a common chromosomal abnormalities in MDS.

The chromosome status at diagnosis and during the course of the disease is a major prognostic indicator for survival, leukaemic transformation and response to treatment [20],[21] . In most studies, patients with a normal karyotype survived longer and presented leukaemic transformation less frequently than those with an abnormal karyotype [22],[23] . However, in the present study, one patient with RARS having normal kayotype died seven months after diagnosis. Another patient with RA with normal karyotype reported at the time of presentation as well as during follow up transformed to RCMD. While karyotypic evolution frequently represents a poor risk feature, there may be some cases in which it does not correlate with disease acceleration [23] .

Trisomy 8 as a single defect has been generally considered as an intermediate or high risk chromosome abnormality [24] . In our study, one patient with RAEB-II with trisomy 8 transformed to acute leukaemia within 10 months from the time of diagnosis. More studies are needed to accurately evaluate the prognostic significance of karyotype transformation and to show whether specific additional defects may define different prognostic subsets of patients.

The distribution of specific chromosomal abnormalities characterized in the subtypes of leukaemia varies between Western and Asian countries [25] . Geographical and ethnic differences in the frequency of specific chromosomal aberrations have also been reported [26] . The incidence of all chromosomal abnormalities has been reported to vary between 37and 88 per cent in the Indian population and 37 and 50 per cent in China, Thailand, Japan and other European and Western countries [9],[10],[13],[16],[17] .

While the pathogenesis of MDS is still poorly understood, environmental, biological and occupational factors could induce mechanisms that are associated with diverse karyotypes and variable frequency of chromosomal abnormalities [27],[28] . Thus, genetic load and degree of exposure to aetiological agents in various countries owing to socio-economic standards may explain the differences in the incidence and of non-random chromosomal abnormalities among MDS patients in different geographical locations. Taken together, these factors may have a significant contribution in the pathogenesis and variability in the demographic and cytogenetic profile of MDS patients all over the world.

In conclusion, our findings provided an overview of the cytogenetic profile of MDS from India and identified previously undescribed prognostically relevant cytogenetic abnormalities. Presently, cytogenetic investigations in India are performed in only a few hospitals. Prospective studies on a large number of patients help elucidate more precisely the demographic and ethnic differences in the pathogenesis of MDS from different parts of the world.


   Acknowledgment Top


Authors thank Ms. Ashima Khanna for the sample collection. The study was supported by Indian Council of Medical Research (ICMR), New Delhi. The first author (RC) acknowledges the ICMR, New Delhi, for the research fellowship.

 
   References Top

1.Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004; 41 : 6-12.  Back to cited text no. 1
    
2.Verma N, Verma S. Proliferative indices, cytogenetics, immunophenotype and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol.Microbiol 2008; 51 : 97-101.  Back to cited text no. 2
    
3.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The French-American-British (FAB) co-operative Group; proposals for the classification of myelodysplastic syndromes. Br J Haematol 1982; 51 : 189-99.  Back to cited text no. 3
    
4.Haase D, Germing H, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110 : 4385-95.  Back to cited text no. 4
    
5.Solé F, Luño E, Sanzo C, Espinet B, Sanz GF. Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90 : 1168-78.  Back to cited text no. 5
    
6.Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol 2005; 84 : 298-303.  Back to cited text no. 6
    
7.Mitelman F. ISCN: an International System for Human Cytogenetics Nomenclature. Basel: Karger; 1991.   Back to cited text no. 7
    
8.Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leu Lymph 1996; 23 : 253-66.  Back to cited text no. 8
    
9.Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87 : 515-26.  Back to cited text no. 9
    
10.Yoshida Y, Oguma S, Uchino H, Maekawa T. Clinical features and prognosis of refractory myelodysplastic anemias: a Japanese Cooperative Study. Nippon Ketsueki Gakkai Zasshi 1987; 50 : 37-45.  Back to cited text no. 10
    
11.Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leukemia 1995; 9 : 219-31.  Back to cited text no. 11
    
12.Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H. Prevelance of the myelodysplastic syndromes in Japan. Int J Hematol 1995; 61 : 17-22.  Back to cited text no. 12
    
13.Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7 : 499-508.  Back to cited text no. 13
    
14.Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymph 2007; 48 : 1372-8.  Back to cited text no. 14
    
15.Mukiibi JM, Paul B. Myelodysplastic syndromes (MDS) in Central Africans. Trop Geogr Med 1994; 46 : 17-9.  Back to cited text no. 15
    
16.Intragumtornchai T, Prayoonwiwat W, Swasdikul D, Suwanwela N, Chaimongkol B, Jootar S, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998; 22 : 453-60.  Back to cited text no. 16
    
17.Mansoor AM, Bharadwaj TP, Sethuraman S, Chandy M, Pushpa V, Kamada N, et al. Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet 1993; 65 : 12-20.  Back to cited text no. 17
    
18.Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110 : 4385-95.  Back to cited text no. 18
    
19.Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4 : 325-45.  Back to cited text no. 19
    
20.Kadam P, Dadabhoy K, Bhisey A, Athale U, Nair C, Nair R, et al. Chromosome investigations and clinical outcome in patients with myelodysplastic syndromes. Indian J Med Res 1995;. 101 : 163-9.  Back to cited text no. 20
    
21.Verhoef G, De-wolf-Peeters C, Kerim S, Van de Broeck J, Mecucci C, Van Den Berghe H, et al. Update on prognostic implication of morphology, histology, and karyotype in primary myelodysplastic syndromes. Hematol Pathol 1991; 5 : 163-75.  Back to cited text no. 21
    
22.Musilova J, Michalova K, Zemanova Z, Neuwithova R, Dohnalova A and the Czechoslovak MDS Cooperative Group. Karyotype at diagnosis, subsequent leukemic transformation and survival in myelodysplastic syndrome. Leuk Res 1995; 19 : 303-8.  Back to cited text no. 22
    
23.White AD, Hoy TG, Jacob's A. Extended cytogenetic follow up and clinical progress in patients with myelodysplastic syndromes. Leuk Lymph 1994; 12 : 401-12.  Back to cited text no. 23
    
24.White AD, Culligan DJ, Hoy TG, Jacob's A. Extended cytogenetic follow up of patients with myelodysplastic syndromes. Br J Hematol 1992; 81 : 499-502.  Back to cited text no. 24
    
25.Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108 : 346-56.  Back to cited text no. 25
    
26.Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer 1991; 3 : 1-7.   Back to cited text no. 26
    
27.Mitelman F. Geographic heterogeneity of chromosome aberrations in hematologic disorders. Cancer Genet Cytogenet 1986; 20 : 203-8.  Back to cited text no. 27
    
28.Davico L, Sacerdote C, Ciccone G, Pegoraro L, Kerim S, Ponzio G, et al. Chromosome 8, occupational exposures, smoking, and acute nonlymphocytic leukemias: a population-based study. Cancer Epidemiol Biomarkers Prev 1998; 7 : 1123-5.  Back to cited text no. 28
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Material & Methods
   Results
   Discussion
   Acknowledgment
    References
    Article Tables

 Article Access Statistics
    Viewed1084    
    Printed60    
    Emailed1    
    PDF Downloaded261    
    Comments [Add]    

Recommend this journal